Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study - Université de Bretagne Occidentale
Journal Articles Haematologica Year : 2017

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

Pieternella Lugtenburg
  • Function : Author
Henriette Berenschot
  • Function : Author
Osman Ilhan
Jean Pierre Marolleau
  • Function : Author
  • PersonId : 887235
  • IdRef : 06981676X
Arnon Nagler
  • Function : Author
  • PersonId : 973523
Antonio Rueda
  • Function : Author
Monica Tani
  • Function : Author
Mehmet Turgut
  • Function : Author
Stuart Osborne
  • Function : Author
Rodney Smith
  • Function : Author
Adrian Tempescul
  • Function : Author
  • PersonId : 908115
No file

Dates and versions

hal-02049783 , version 1 (26-02-2019)

Identifiers

  • HAL Id : hal-02049783 , version 1

Cite

Pieternella Lugtenburg, Irit Avivi, Henriette Berenschot, Osman Ilhan, Jean Pierre Marolleau, et al.. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica, 2017, 102 (11), pp.1913-1922. ⟨hal-02049783⟩
23 View
0 Download

Share

More